Investigating the effects of renal nerve denervation on kidney function
Official title: Effect of RDN on Renal Function
Run by The First Affiliated Hospital of Xiamen University · NCT05612906 · Data updated 2026-11-12
This study is testing if a procedure called renal nerve denervation can improve kidney function in adults with high blood pressure who haven't had success with other medications.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | The First Affiliated Hospital of Xiamen University Academic / other |
| Locations | 1 site (Xiamen, Fujian) |
| Status | Recruiting |
| Started | June 1, 2022 |
| Main results expected | December 31, 2023 |
| Study ends | December 1, 2026 |
| Registry record updated | February 27, 2025 |
| Trial ID | NCT05612906 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 75 with resistant hypertension who are willing to undergo renal nerve denervation.
✕Probably not a fit
Patients with secondary hypertension, severe systemic diseases, or unsuitable renal arteries for ablation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the impact of renal nerve denervation (RDN) on renal function in patients with hypertension. It will include individuals aged 18 to 75 who have essential hypertension or related conditions and have not responded adequately to multiple antihypertensive medications. The study will assess renal function before and after the RDN procedure to determine its safety and efficacy. Participants will be required to provide informed consent and meet specific inclusion criteria.
Why it matters
Potential benefit: If successful, this study could provide insights into the safety of RDN and its potential to improve kidney function in hypertensive patients.
How similar studies have gone: While RDN has shown promise in treating hypertension, the specific effects on renal function are still being explored, making this study a valuable addition to existing research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
1.18\<age≤75 years; 2.clinic blood pressure ≥ 140/90 mmHg or 24-hour ambulatory blood pressure monitoring average blood pressure ≥ 135/85 mmHg after taking 3 or more antihypertensive drugs for more than 4 weeks; 3.essential hypertension, renal parenchymal hypertension, or hypertension patients who are willing to receive RDN ; 4.who signed informed consent and were approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University.
Exclusion Criteria:
* pregnant women or lactating patients;
* identified secondary hypertension or Pseudo hypertension;
* whose renal arteries were unsuitable for ablation
* obvious bleeding tendency and blood system diseases;
* malignant tumors or end-stage diseases; ⑥Severe peripheral vascular disease, abdominal aortic aneurysm; ⑦A history of the acute coronary syndrome within two weeks; ⑧acute or severe systemic infection; ⑨drug or alcohol dependence or refusal to sign informed consent.
Where it's running
-
zhengrong Huang
Xiamen, Fujian, China Recruiting
Study contacts
- Study coordinator: Zhengrong Huang, M.D.
- Email: huangzhengrong@xmu.edu.cn
- Phone: +8613606028353
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
68Ga-XHER2 PET/CT imaging to see HER2 in solid tumors
A noninvasive PET/CT imaging test using 68Ga-XHER2 is being tried to see if it reflects HER2 levels in solid tumors.
-
68Ga-XMFH01 PET/FL imaging to guide prostate cancer surgery
This study tests a new dual-modality imaging probe, 68Ga-XMFH01, to preoperatively detect prostate cancer and guide the surgeon with fluorescence during operations in adults with newly diagnosed prostate cancer.
-
Anxiety and Depression in Patients with Hematologic Cancers
This study tests whether anxiety and depression levels before and after treatment are linked to treatment outcomes in people newly diagnosed with lymphoma, multiple myeloma, or leukemia.
-
VCC combination in relapsed or refractory AML
A group of adults with relapsed or refractory AML will receive a three-drug combo (venetoclax, chidamide, and chiglitazar sodium) to see if it helps control the leukemia.
-
Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL
This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.
-
Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer
This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.